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University of Western Ontario IDDM (Table 1), including the polygenic control reflected
by the inheritance of particular MHC class II alleles andLondon, Ontario
Canada N6G 2V4 multiple non-MHC loci as genetic risk factors; the trans-
mission of disease by bone marrow±derived hematopoi-
etic stem cells; the early appearance of an intra-islet
inflammatory infiltrate (insulitis) and anti-islet cell anti-Who is more contemptible than he who scorns knowl-
edge of himself?ÐJohn of Salisbury bodies; and the autoreactive T cell dependence of IDDM
pathogenesis and the ability to intervene with disease
This statement reflects our concern about the factors, progression by modulation of T cell function (Bach,
1994; Bowman et al., 1994; Tisch and McDevitt, 1996).both internaland external, that control our lives. Unfortu-
nately, there are times when our immune system, which Considerable evidence suggests that IDDM in NOD
mice is mediated by T cells. IDDM is prevented by neo-normally protects us from adverse infections and dis-
eases, scorns our body and mounts an autoaggressive natal thymectomy, by immunosuppressive agents that
target T cells, and by anti-CD4 and anti-CD8 monoclonalattack against it, resulting in autoimmune disease.
Among the many severely debilitating autoimmune dis- antibody treatments. Furthermore, IDDM can be adop-
tively transferred to neonatal NOD mice and immunode-eases are multiple sclerosis, rheumatoid arthritis, and
insulin-dependent diabetes mellitus (IDDM), or type 1 ficient NOD.SCID (severe combined immunodeficiency)
mice by T cells from spontaneously diabetic adult NODdiabetes. What are the factors, both genetic and envi-
ronmental (diet and infection) that mediate the onset of mice.
IDDM pathogenesis in NOD mice is heralded by thethese diseases? How do we identify these factors? And
how can we control these factors in order to prevent the infiltrationÐfirst by dendritic cells and macrophages
and then by T cells (CD41 and CD81) and B cellsÐof theonset of autoimmune diseases? Studies of autoimmune
diseases in representative animal models have proven perivascular duct and peri-islet regions of thepancreatic
islets of Langerhans (peri-insulitis) beginning at 3±4to be very informative.
This review focuses on the use of one such animal weeks of age. This stage is followed by the slow, pro-
gressive, and selective T cell±mediated destruction ofmodel, the nonobese diabetic (NOD) mouse, which
spontaneously develops IDDM. The NOD mouse has insulin-producing islet b cells by 4±6 months of age.
Whereas a nondestructive peri-insulitis is observed inbecome the most extensively studied model of sponta-
neous organ-specific autoimmune disease. Excellent re- all female and male NOD mice, NOD females develop a
more invasive and destructive insulitis and incur a higherviews exist on the origin, genetics, immunological char-
acteristics, and influence of environmental factors on incidence (80%±90%) of IDDM than males (10%±40%).
This pronounced female gender bias is not observed inIDDM in NOD mice (Kikutani and Makino, 1992; Leiter
and Serreze, 1992). Importantly, experiments conducted humans.
A consensus view of the factors eliciting IDDM in thewith NOD mice in recent years have begun to provide
clues about how we may modulate and regulate the NOD mouse is that dysregulation of the immune re-
sponse is a principal factor: an excess of islet antigen±immune response in order to protect against IDDM in
humans (Bowman et al., 1994; Bach and Mathis, 1997). specific T helper type 1 (Th1) cells arise, perhaps as a
consequence of a deficiency in regulatory or suppressorThe central questions that we address in this review
are: What are the immunological mechanism(s) that in- T cells.
duce this T cell±mediated autoimmune disease? Is there
a single mechanism that elicits IDDM or are there multi- T Cell Responses to Autoantigens in IDDM:
ple mechanisms? Different mechanisms of IDDM induc- Are They Relevant?
tion have been proposed, including (1) expression of Both T cellsand B cells reactive to islet antigens infiltrate
diabetogenic major histocompatibility complex (MHC) the pancreatic islets at the inflammatory stage of insu-
class II allelic products that bind peptides with low affin- litis. Do these infiltrated B cells play a role in the etio-
ity, enabling self-reactive T cells to escape from the pathogenesis of IDDM? Autoantibodies against several
thymus to the periphery; (2) positive selection of specific islet autoantigens, such as insulin, glutamic acid decar-
T cell antigen receptors (TCR) that recognize primary boxylase 65 (GAD65), and IA-2, a cytoplasmic tyrosine
autoantigen(s); (3) breaking of peripheral tolerance by phosphatase, are present in the sera of humans with
pathogenic infection; and (4) deficient activation of regu- IDDM for several years before theonset of overtdisease,
latory T cells, resulting in deficient immune regulation. but a direct role for these autoantibodies in the patho-
genesis of IDDM remains uncertain. Evidence exists that
B cells themselves may play an important role in the*To whom correspondence should be addressed (e-mail: del@
rri.on.ca). etiology of IDDM. B cell±deficient (Igmnull) (Serreze et
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Table 1. Functional T Cell Defects in NOD Mice
T Cell Population Defect Associated with Restored by References
Splenic T cells SMLR response CD41 T cell defect IL-2 Serreze and Leiter, 1988
Reduced IL-2 production
Thymocytes and Response to TCR Deficient PKC/Ras/MAPK IL-2 (partially) Rapoport et al., 1993a
peripheral T cells stimulation signaling pathway IL-4 (completely) Rapoport et al., 1993b
Salojin et al., 1997b
Reduced IL-2 and IL-4 Anti-CD28 monoclonal Arreaza et al., 1997
production antibody
Intrathymic and Maturation Reduced IL-4 production IL-7 Gombert et al., 1996a
peripheral NK-like Gombert et al., 1996b
T cells
MAPK, mitogen-activated protein kinase.
al., 1996) or anti-Igm±treated female NOD mice (Noor- What Role Do MHC Molecules Play in IDDM?
Do any of the IDDM-susceptibility loci control the func-chashm et al., 1997) develop neither insulitis nor IDDM.
Although this result has raised some controversy, it is tion of autoreactive effector and regulatory T cells?
The inheritance of particular MHC class II alleles consti-possible that the main role of B cells in the immuno-
pathogenesis of IDDM may not be to secrete autoanti- tutes one of the most important genetic risk factors for
susceptibility to IDDM (Wicker et al., 1995; Tisch andbodies but rather to present autoantigens to islet b cell±
reactive CD41 T cells. McDevitt, 1996; Vyse and Todd, 1996; Wicker, 1997).
The unusual H-2g7 MHC haplotype of NOD mice (Kd, I-Ag7,Accordingly, attention has been focused in recent
years on the role of T cells reactive against islet autoanti- I-Enull, Db), which maps in the Idd-1 susceptibility locus
on chromosome 17, contributes to several dysfunctionsgens. The identity of islet b cell antigens that may be
targets of autoimmune T cells remains controversial, of antigen-presenting cells (APC) that may promote the
development of islet b cell±autoreactive T cells (Atkin-and several different autoantigens have been implicated
(Singh et al., 1998; Zechel et al., 1997). Nevertheless, son, 1997). The I-Abg7 allele in NOD mice and certain
human leukocyte antigen (HLA)±DQb alleles in humansthe importance of autoantigens in the etiopathogenesis
of IDDM is supported by several lines of study. For that encode serine, alanine, or valine at position 57 medi-
ate IDDM susceptibility, whereas aspartic acid at posi-example, unlike spleen cells from NOD mice, spleen
cells from b cell±depleted NOD mice cannot adoptively tion 57 is associated with IDDM resistance. Mutation of
the I-Abg7 gene to contain Asp57 reduces the incidencetransfer IDDM to irradiated NOD mice (Larger et al.,
1995), suggesting that b cell autoantigens must be pres- of IDDM but does not prevent insulitis, sialitis, or the
development of insulin and nuclear autoantibodiesent continuously for development of IDDM. Additional
evidence for antigen-driven autoimmunity in IDDM is the (Lund et al., 1990). This result indicates that alteration
of I-Ag7 neither prevents the homing of T cells to theloss of self-tolerance in NOD mice upon immunization
with antigenic self-peptides (Ridgeway et al., 1996). pancreas or salivary glands nor eliminates autoreactive
T cells, but rather blocks the progression to overt IDDM.Candidate primary autoantigens for the development
of IDDM are GAD65 (or the mouse GAD67 isoform), insu- When I-Ag7 is expressed in the heterozygous state to-
gether with various other non±I-Ag7 class II molecules inlin, proinsulin, and heat shock protein 60 (hsp60). T cell
responsiveness to GAD65 (Kaufman et al., 1993; Tisch NOD mice, these mice all are resistant to the onset of
IDDM (Schmidt et al., 1997). Thus, an IDDM-resistantet al., 1993) and insulin (Daniel et al., 1994) is detectable
by 3±4 weeks of age in NOD mice, and the induction of MHC class II allele on one haplotype may dominate
an IDDM-susceptible MHC class II allele on a secondneonatal tolerance to GAD65 eliminates the subsequent
development of insulitis and IDDM (Kaufman et al., 1993; haplotype.
The reason that homozygosity at H-2g7 is necessaryTisch et al., 1993; Tian et al., 1996). Treatment of mice
with either insulin or insulin B chain (Zhang et al., 1991; but not sufficient for the development of IDDM may be
that I-Ag7 MHC class II molecules are unable to presentBergerot et al., 1994; Muir et al., 1995), proinsulin (Har-
rison et al., 1996) or the hsp60 peptide p277 (Cohen, antigen efficiently to b cell antigen±autoreactive T cells.
That is, deletion of self-reactive T cell clones may require1997; Elias et al., 1997) also prevents IDDM and down-
regulates responses to the other three autoantigens, a threshold of peptide±MHC complexes that persist on
APCs for a finite period of time (Sprent et al., 1988;respectively. Of the more than ten known islet autoanti-
gens targeted in IDDM, insulin is the only one expressed Milich et al., 1989; Ashton-Rickhardt and Tonegawa,
1994). It is possible that the threshold and time of pep-specifically by b cells. Nonetheless, insulin, proinsulin,
and GAD65 are each unable to elicit IDDM upon active tide±MHC expression on APCs in the thymus of an NOD
mouse are not sufficient for negative selection of autore-immunization of NOD mice, and only a transient hyper-
glycemia and insulitis are induced by hsp60 or its p277 active T cells by induction of their apoptosis (Serreze,
1993). Indeed, alterations in the differentiation and func-peptide (Elias et al., 1995). Thus, at present it is difficult
to assign a ªprimary diabetogenic antigenº status to a tion of APCs in NOD mice have been reported (Serreze
et al., 1993a, 1993b).single islet autoantigen, consistent with the notion that
IDDM in NOD mice and humans is associated with T That the process of negative selection or inactivation
of islet-specific T cells may be deficient in NOD mice iscell reactivity to many antigen specificities (Roep, 1996).
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supported by the recent report that I-Ag7 MHC class II on a viral protein and autoantigen(s). It is thought that
most T cell epitopes of an autoantigen are not availablemolecules bind peptides of an islet autoantigen with
only low affinity, preventing efficient presentation by for recognition by T cells in the thymus, enabling autore-
active T cells to escape thymic tolerance and to existNOD APCs to autoreactive T cells (Carrasco-Marin et
al., 1996). In a NOD thymus, inefficient MHC class II± in the peripheral T cell pool of healthy individuals and
animals (Weckerle et al., 1996). Autoantigenic epitopesmediated autoantigen presentation by APCs in the thy-
mus could result in failure to delete potentially autoreac- might not be recognized in the thymus, either because
they are not recognized by T cells (cryptic epitopes) ortive T cells, which then exit the thymus and induce
autoimmune IDDM. Indeed, T cells from NOD mice have because they are not generated in sufficient amounts
to bind to MHC molecules (Sercarz et al., 1993). T cellsbeen found to display an abnormally high reactivity to
self-proteins (Ridgeway et al., 1996). In addition, it ap- specific for these cryptic epitopes may suddenly be-
come evident as a result of a pathogenic viral infection.pears that more autoreactive T cells escape from the
thymus in NOD mice than in mice resistant to autoim- Accordingly, by molecular mimicry, T cell reactivity to
an infectious viral antigen may result in activation andmune disease. These observations provide additional
support for the earlier findings that autoreactive T cells expansion of T cells cross-reactive with an autoantigen.
Is there evidence for molecular mimicry in T cell±are able to activate low-level effector T cell responses
in NOD mice (Haskins et al., 1989) and that relatively mediated autoimmune disease? It is known that experi-
mental acute and persistent infections with DNA or RNAfew peptides can be eluted from I-Ag7 molecules (Reich
et al., 1994). viruses can induce, accelerate, or enhance autoimmune
responses and cause autoimmune disease (Oldstone,Nevertheless, support for a central role of I-Ag7 in the
generation of pathogenic T cells is not universal. I-Ag7 1988). In fact, molecular mimicry has been shown to
exist between T cell epitopes of a viral protein and anmolecules have not been found deficient in either the
binding or the presentation of certain autoantigen pep- autoantigen in multiple sclerosis, namely myelin basic
protein. Evidence in support of the molecular mimicrytides (Harrison et al., 1997; Reizis et al., 1997; Zechel et
al., 1997). In addition, it has been difficult to detect T cell hypothesis for IDDM (Oldstone, 1997) is that infections
with Coxsackie B4 and rubella viruses have each beenautoreactivity to islet autoantigens in naive, prediabetic
NOD mice. Nevertheless, I-Ag7 in mice (Carrasco-Marin linked to the induction of IDDM (Forrest et al., 1971;
Gamble et al., 1973; Notkins et al., 1984). Interestingly,et al., 1996, 1997) and HLA-DQ3.2 in humans (Buckner
et al., 1996) appear to bind most peptides with low avid- one of the epitopes of the GAD65 islet cell autoantigen
has apparent structural homology to an epitope of theity, as determined by decreased stability of their pep-
tide±MHC complexes upondenaturation in SDS. In T cell Coxsackie B4 virus (Tian et al., 1994). Moreover, a T
cell proliferative response shared between GAD65 andassays, immunogenic peptides, including those from
diabetogenic autoantigens, appear to have a fast rate Coxsackie B4 was found among 25% of 16 patients with
a new diagnosis of IDDM but among none of 13 healthyof dissociation from I-Ag7 molecules, in that the peptide-
pulsed NOD APCs are easily washed free of peptide. matched control subjects (Atkinson et al., 1994). None-
theless, reciprocal cross-reactivity between anti-GAD65Despite the weak binding of I-Ag7 molecules, it is clear
that NOD APCs can still present peptides to reactive antibodies and anti-Coxsackie B4 antibodies with Cox-
sackie B4 and GAD65, respectively, which would sup-T cells. It is possible that other accessory molecules
compensate for the low peptide-binding affinity of I-Ag7. port the molecular mimicry hypothesis, has not yet been
found. The role of enteroviruses in the etiology of IDDMFor example, non±MHC-linked genes encoding costim-
ulatory molecules may affect the activation threshold of is presently inconclusive (Graves et al., 1997).
Thus, an immune response elicited against an in-T cells in either the thymus or the periphery, and the
expression of such costimulatory molecules may be al- fecting pathogen may cross-react with self-antigens
that share determinants with that pathogen so that antered in response to low-affinity peptide±MHC com-
plexes. Indeed, impaired expression of costimulatory autoimmune disease may be initiated or aggravated by
viral infections. Persistent viral infection may explainmolecules (CD28) or their ligands (B7-1 and B7-2) on T
cells and APCs underlies abnormal T cell activation and why T cells infiltrate not only the pancreas in NOD mice
anergy in several autoimmune diseases in mice and hu- but also several other glands (the submandibular salivary
mans (Tivol et al., 1996; Salojin et al., 1997a), including glands, thyroid, lachrymal glands, ovary, and testes),
IDDM. Interestingly, it has been suggested that up-regu- indicating that NOD mice exhibit many T cell±mediated
lation of B7-1 expression activates Th1 cells predomi- inflammatory responses (Bach, 1994). However, it should
nantly, while generation of Th2 cells is more dependent be kept in mind that infectious agents do not invariably
on the CD28/B7-2 pathway. This scenario indicates that increase the incidence of IDDM, since the incidence
generation of Th1 versus Th2 cells is influenced by lim- of IDDM is highest in NOD mouse colonies housed in
iting CD28-B7 costimulation. specific pathogen±free facilities. Some viral infections
even prevent IDDM (von Herrath and Oldstone, 1996).
Regarding specific pathogens and their potential roleDoes Molecular Mimicry between Viruses and Islet
Autoantigens Break Self-Tolerance and Elicit IDDM? in the cause of IDDM, superantigens have been impli-
cated in human IDDM (Conrad et al., 1994). More re-Molecular mimicry has received considerable attention
in recent years in attempts to explain the activation cently, a new endogenous retroviral genome was impli-
cated in the pathogenesis of human IDDM (Conrad etand expansion of autoreactive T cells in the periphery.
Molecular mimicry, defined by three-dimensional struc- al., 1997). An envelope protein of this retrovirus encodes
a superantigen that preferentially expands the Vb71 Ttural homology, is postulated to exist for T cell epitopes
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cell subset in IDDM patients. This protein has homology detection at the time of insulitis and subsequently during
progression to IDDM (Yang et al., 1996). This problemwith the mouse mammary tumor virus±derived endoge-
nous retroviral superantigen. Thus, this endogeneous necessitated analyses of TCR expression by T cells at
time points preceding histologically detectable infiltra-superantigen provides evidence for the involvement of
a pancreatic islet cell membrane-bound superantigen tion. Assay of the TCR Vb repertoire of islet-infiltrating
T cells in very young NOD mice revealed that one mono-as a candidate autoimmune gene in IDDM. It has been
postulated that the endogeneous retroviral genome is clonal TCR Vb8.2 gene product is expressed by T cells
infiltrating the islets of these mice at 2 weeks of agetranscribed in lymphocytes and that the superantigen
may activate T cells in association with class II MHC (Yang et al., 1996). The resultant inflammatory response
rapidly obscures the monoclonal nature of the initiatingmolecules. The role of endogeneous retroviral transcripts
in the islet cells has also been suggested in IDDM in event. These findings suggest that IDDM in NOD mice
may be initiated by the recognition of a single autoan-NOD mice (Gaskins et al. 1992).
tigen.
More recently, it has also been shown that the majorityIs the Onset of IDDM Mediated by T Cell Clones
That Possess a Restricted T Cell Repertoire? of T cell clones isolated from spontaneous islet lesions
of prediabetic female NOD mice of 4±12 weeks of ageThe events that initiate IDDM are not well understood.
It is possible that the association between MHC class are diabetogenic when adoptively transferred and react
with a single autoantigen peptide consisting of residuesII molecules and IDDM susceptibility in NOD mice may
be due to the recognition of a single MHC class II± 9±23 of the insulin B chain (Simone et al., 1997). This
subset of insulin B9±23±reactive T cell clones expressesrestricted antigenic determinant by a clone of autoreac-
tive T cells. Such recognition could lead to an autoim- no detectable TCR Vb restriction but is restricted to the
expression of a single TCR Va13.3 chain combined withmune response and promote the onset of IDDM,
consistent with the notion that several autoimmune dis- the Ja45 or Ja34 segments. These data suggest that
immunodominant insulin B chain peptides recognizedorders may be linked to the restricted use of TCR gene
segments (Nepom and Erlich, 1991). In this case, a re- predominantly by restricted TCR Va chains may play a
major role in progression to IDDM in NOD mice, in sup-stricted T cell repertoire targeted to a major autoantigen
may represent an important early event in the onset of port of the efficacy of preventive insulin B chain therapy
of NOD IDDM (Zhang et al., 1991; Bergerot et al., 1994;IDDM. This hypothesis is supported by animal models
of experimentally induced autoimmune diseases, such Muir et al., 1995; Daniel and Wegmann, 1996; Berg-
erot et al., 1997). Similarly, islet-infiltrated MHC classas experimental autoimmune encephalomyelitis, in which
immunization with determinants of an autoantigen (my- I±restricted CD81 T cell clones obtained from diabetic
NOD mice use strikingly homologous TCR Va and Vbelin basic protein) leads to monoclonal T cell responses
that initiate inflammatory responses and ensuing dis- gene sequences (Santamaria et al., 1995), suggesting
that infiltrated CD81 T cells may also recognize a moreease. It has proven challenging to develop a test of
this hypothesis in an animal model of an autoimmune restricted set of b cell autoantigen epitopes even after
the onset of IDDM. Thus, a limited expression of TCRdisease that develops spontaneously, such as IDDM in
NOD mice. Va and Vb genes by certain subsets of pathogenic T cells
may be associated with IDDM onset, but a consensusMany investigators have isolated islet antigen±specific
T cell clones from the periphery as well as lesions of awaits further experimentation on a much larger number
of islet-infiltrating (early and late) T cell clones in bothinsulitis from both prediabetic and diabetic NOD mice
and have shown that these T cells express many differ- prediabetic and diabetic NOD mice.
ent TCRs (Haskins et al., 1988, 1989; Maeda et al., 1991;
Nakano et al., 1991; Zipris et al., 1991a; Waters et al., Does an Imbalance Between Thl and Th2 Cell
Activation Arise in NOD Mice, and Is This1992; Toyoda et al., 1992; Galley and Danska, 1995;
Daniel and Wegmann, 1996; Komagata et al., 1996; Fox Imbalance Crucial in Determining Whether
Autoimmune T Cell Reactivityand Danska, 1997). These results have suggested that
such islet-specific T cells recognize several different Results in IDDM?
Considerable evidence indicates that cooperation be-antigens. A more rigorous test of whether a restricted
T cell repertoire initiates IDDM requires extensive analy- tween CD41 and CD81 T cells is required to promote
development of IDDM in NOD mice (Bendelac et al.,sis of TCR expression by islet-infiltrating T cells in very
young IDDM-prone NOD mice, at the onset of insulitis at 1987; Christianson et al., 1993) and that islet b cell
destruction is mediated by both CD41 (Haskins and1 month of age and even prior to insulitis. As previously
demonstrated, islet-infiltrating CD41 T cells examined McDuffie, 1990; Christianson et al., 1993; Rohane et al.,
1995) and CD81 (Wicker et al., 1995; Kay et al., 1996;at the time of insulitis express a heterogeneous array
of TCR variable (V) b gene products (Maeda et al., 1991; Serreze at al., 1996; Wang et al., 1996; Wong et al., 1996)
T cells. Included among the effector cells of IDDM inNakano et al., 1991; Zipris et al., 1991a; Toyoda et al.,
1992; Waters et al., 1992; Galley and Danska, 1995). NOD mice are CD41 Th1 cells, which preferentially se-
crete interferon-g (IFNg) and tumor necrosis factor-aBecause of T cell recruitment, inflammation, determinant
spreading of the autoimmune response, or a combina- (TNFa) (Rabinovitch, 1994; Katz et al., 1995; Liblau et
al., 1995; Pilstrom et al., 1995; Trembleau et al., 1995;tion of these, it has been proposed that a TCR-restricted
monoclonal population of islet-infiltrated T cells that rec- Shimada et al., 1996; Elias et al., 1997; von Herrath and
Oldstone, 1997). Current evidence, albeit indirect, sug-ognize a single b cell autoantigen initiates islet infiltra-
tion, but because of very low frequency may escape gests that these effector Th1 cells and susceptibility
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to IDDM may be regulated by CD41 Th2 cells, which et al., 1997). At this age, a high ratio of IFNg/IL-4 expres-
preferentially secrete interleukin-4 (IL-4), IL-5, IL-6, IL- sion can be found in the islet-infiltrated T cells of female
10, and IL-13 (Rabinovitch, 1994; Liblau et al., 1995). NOD mice, and this ratio is predictive both of the onset
Cell transfer experiments indicate that CD41 cells initi- of destructive insulitis and of a high incidence of IDDM
ate IDDM and that Th1 cells may be effector cells of in NOD females (Fox and Danska, 1997). In contrast, a
disease in NOD mice, although CD81 cells may also high ratio of IL-4/IFNg expression is detected in the islet-
play an effector role and be responsible for the final infiltrated T cells of male NOD mice, and the predomi-
destruction of islet b cells. The role of CD81 T cells in nant IL-4 expression at the onset of islet inflammation
IDDM in NOD mice has been addressed in a number of predicts the onset of a nondestructive insulitis and a
ways. It has been shown that b2-microglobulin (b2m)± low incidence of IDDM in male NOD mice. Thus, it is
deficient NOD mice (NOD-b2mnull) lacking MHC class I plausible that these variations in cytokine secretion may
molecules, and hence CD81 T cells, do not develop elicit a Th1/Th2 imbalance in4- to 6-week-old NOD mice.
IDDM or insulitis (Serreze et al., 1994; Wicker et al., More significantly, this pattern of differential cytokine
1994). Expression of a b2m transgene in NOD-b2mnull expression in young female NOD mice may explain why
mice resulted in reconstitution of IFNg-inducible cell- several types of treatment of IDDM, including autoanti-
surface MHC class I protein on islet b cells. These mice gen-induced tolerance (Elliot et al., 1994; Tian et al.,
developed insulitis but did not develop IDDM. These 1996), cytokine (IL-4)±mediated therapy (Rapoport et al.,
studies demonstrate that b2m expression and cell-sur- 1993a; Mueller et al., 1996; Cameron et al., 1997a), and
face MHC class I expression on islet b cells are essential costimulation (CD28/B7)±mediated (Lenschow et al.,
for the initiation of IDDM in the NOD mouse and further 1996; Arreaza et al., 1997) therapy, are most effective
confirm that efficient progression to diabetes requires when administered to NOD mice beginning at 2±3 weeks
both CD41 and CD81 T cells (Kay et al., 1996, 1997). of age.
Furthermore, CD81 islet cell±specific cytolytic T cell What causes these early changes in T cell immunoreg-
lines and clones from NOD mice can transfer IDDM to ulation in young NOD mice? It is possible that these
irradiated NOD mice if coinjected with nondiabetogenic changes are induced by a bacterial infection. Both IFNg
CD41 spleen T cells (Christianson et al., 1993; Wang et expression and Th1 cell development are stimulated by
al., 1996). Therefore, CD81 T cells as final effector cells IL-12. The administration of IL-12 induces the rapid on-
in IDDM require signals from CD41 T cells to effect b cell
set of IDDM, and the pancreatic expression of IL-12
damage. However, in some cases when islet-reactive
correlates with IDDM development in NOD mice (Trem-
CD81 T cells are adoptively transferred to irradiated
bleau et al., 1995). Several bacterial products are en-
female NOD or NOD.SCID mice, IDDM occurs very rap-
hanced by bacterial infection, including lipopolysaccha-
idly and without CD41 T cells (Wong et al., 1996, 1997).
ride and bacterial DNA, which potently induce IL-12
TCR transgenic NOD mice with a CD41 T cell repertoire
production by macrophages. Thus, an adverse bacterialhighly skewed for an anti-islet cell reactivity do not de-
infection in a young NOD mouse may stimulate the pro-velop insulitis upon b2m deletion or treatment with anti-
duction of IL-12, upset the Th1/Th2 balance in favor ofCD8 antibody (Wang et al., 1996). These results also
a dominant Th1 milieu, and thereby elicit the onset ofsuggest that CD81 cells are required for effective prim-
insulitis and IDDM. Further experimentation will being and expansion of autoreactive CD41 cells in TCR
needed to determine the relevance of this interestingtransgenic mice.
scenario.Evidence consistent with the presence of regulatory
Another scenario, which may account for the age-CD41 T cells in prediabetic NOD mice is provided by
related decline in regulatory CD41 T cell function in NODreports that cyclophosphamide induces acute IDDM
mice, is an induced state of anergy in young NOD mice.(Charlton et al., 1989); sublethal irradiation is required
If regulatory Th2 cells protect against IDDM, then theto transfer disease by diabetogenic T cells (Wicker et
induction of anergy in regulatory Th2 cells may elicital., 1986); adoptive transfer of IDDM can be blocked by
disease. TCR ligation-induced anergy is manifested bycotransfer of CD41 T cells from young nondiabetic males
T cells in both the thymus and periphery of NOD mice.(Hutchings and Cooke, 1990) or females (Boitard et al.,
This T cell anergy, which is first detectable at the onset1989); and thymectomy and CD4 depletion potentiates
of insulitis and persists until the development of IDDMthe development of IDDM in NOD males (SempeÂ et al.,
in NOD mice, is mediated by a large reduction in IL-21994).
and the virtual absence of IL-4 secretion (Zipris et al.,Curiously, several investigators have found that nu-
1991b; Rapoport et al., 1993a). Complete reversal of thismerous T cell abnormalities emerge in NOD mice (Table
NOD T cell anergy and complete prevention of destruc-1) in an age-related manner. Most notably, these abnor-
tive insulitis and IDDM can be achieved by the systemicmalities are manifest by 4±6 weeks of age, coincident
administration of either IL-4 (Rapoport et al., 1993a;with the time of onset of periinsulitis, and include T cell
Cameron et al., 1997a, 1997b) or an anti-CD28 mono-proliferative hyporesponsiveness upon TCR stimulation
clonal antibody (Arreaza et al., 1997) or by immunostimu-(Zipris et al., 1991b), reduced IL-2 and IL-4 secretion in
lation in vivo with adjuvants (Qin et al., 1993). Each ofresponse to T cell activation (Rapoport et al., 1993a),
these treatments preferentially stimulates the intra-isletand loss of regulatory T cell or suppressor T cell function
production of IL-4, a Th2-derived cytokine required for(Bergerot et al., 1997). Another important change in T
polarization of T cells to the Th2 subset. A significantcell immunoregulation that occurs by the age of 4±6
proportion of regulatory CD41 Th2-like cells may there-weeks in NOD mice is a skewing toward Th1 cells, as
fore be anergic in NOD mice, a notion that is compatiblereflected by the cytokine secretion profiles of islet-infil-
trating T cells (reviewed by Bach et al., 1997; Bergerot with the recently proposed hypothesis that ªregulatory
Immunity
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Th2 cell anergyº can mediate the pathogenesis of IDDM regulatory Th2 cells. NK-like thymocytes and peripheral
T cells (NK-T cells), which proliferate in response to the(Salojin et al., 1997a). Thus, as mentioned above, if
young NOD mice become susceptible to bacterial infec- CD1 MHC class I±like ligand, are believed to be a major
T cell source of IL-4 for the development of Th2 cellstion and this infection enhances the production of IL-
12, the increase in IL-12 concentration may down-regu- (Bendelac et al., 1997). Interestingly, the number and
function of NK-T cells is diminished about 3-fold in thelate IL-4 activity and lead to the anergy of IL-4±secreting
Th2 cells. thymus and periphery of NOD mice at 3 weeks of age,
and anti-CD3±induced IL-4 secretion is barely detect-It appears that the function of Th2 cells may be com-
promised in young NOD mice to a greater extent than able until 8 weeks of age (Gombert et al., 1996a). IL-7
plays a crucial role in the functional maturation of NK-Tthat of Th1 cells, possibly because Th2 cells may pos-
sess a higher activation threshold than Th1 cells. Hence, cells (Vicari et al., 1996) and restores IL-4 production by
stimulated mature NK-T cells in the thymus and spleenregulatory Th2 cells in NOD mice may be insufficiently
stimulated mice to down-regulate diabetogenic Th1 (Gombert et al., 1996b). The NOD NK-T cell defect there-
foremay arise from insufficient IL-7 bioavailability, whichcells reactive against islet b cell autoantigens. Such a
possibility could explain the proposed Th1/Th2 para- contributes to reduced IL-4 production by activated
NOD T cells (Rapoport et al., 1993a; Cameron et al.,digm in IDDM (Liblau et al., 1995; AndreÂ et al., 1996;
Nicholson and Kuchroo, 1996), in which functionally ac- 1997a, 1997b). This deficiency in IL-4 production could
ultimately generate an imbalance between Th1 and Th2tive Th2 cells protect against disease. Strong evidence
for this conclusion is lacking, however, since data both cells, in favor of Th1 cells, in the periphery. Indeed,
administration of IL-7 to NOD mice protects them fromin favor and against this paradigm have been obtained.
While NOD islet infiltrate±derived Th1 cells reactive to IDDM, and this protective effect is mediated by the abil-
ity of IL-7 to restore the differentiation, function, andeither insulin, GAD65, or another unknown islet autoanti-
gen (Daniel et al., 1994; Katz et al., 1995; Daniel and deficit of IL-4±producing T cells in NOD mice (Gombert
et al., 1996b).Wegmann, 1996) and spleen-derived insulin-reactive
Th1 cells (Daniel and Wegmann, 1996) can transfer Thus, a relative lack of IL-4 production by NK-T cells
is associated with and may be causal to the onset ofIDDM, islet-derived CD41 Th1 cells can also prevent
IDDM (Chosich and Harrison, 1993; Akhtar et al., 1995; IDDM. This idea is further supported by the decreased
frequency of IL-4±producing NK-T cells and the impairedTan et al., 1996). Similarly, while IL-4±secreting Th2 cells
(Bergerot et al., 1994; Ploix et al., 1997) and/or Th3 cells IL-4 production by circulating T cells in the peripheral
blood of patients with IDDM (Berman et al., 1996; Wilson(secreting IL-4, IL-10, and transforming growth factor-b)
obtained from the intestinal mucosa of oral insulin±fed et al., 1997). It appears that IDDM is associated with an
extreme Th1 phenotype for NK-T cells. These correla-mice transfer protection from IDDM (Chen et al., 1994),
islet-derived autoantigen specific Th2 cells do not trans- tions between the development of autoimmune T cell
reactivity and deficient CD41 NK-T cell activity and fre-fer protection from IDDM (Katz et al., 1995). Rather, the
latter Th2 cells directly transfer a general pancreatitis quency in the NOD mouse and in patients with IDDM
provide a strong framework for thehypothesis that IDDMinto immunocompromised NOD.SCID mice but not neo-
natal NOD mice (Pakala et al., 1997). In addition, two results from a failure of immune regulation.
insulin-reactive and two GAD65-reactivesplenic Th2 cell
clones each elicited IDDM upon transfer into NOD.SCID What is the Evidence That Immune Dysregulation
Influences the Onset of IDDM?but not neonatal NOD mice (Daniel and Wegmann, 1996).
Further investigation will reveal whether the exceptions Despite the attraction of this ªfailure of immune regula-
tionº hypothesis, the subject of whether NK-T cells areto the Th1 effector paradigm (promotes IDDM) and the
Th2 regulatory paradigm (protects from IDDM) are attrib- involved in the control of Th2 cell differentiation has
been debated. While NK-T cells are not obligatory for allutable to differences in the tissue of origin, antigen spec-
ificity, ability tohome to pancreatic islets, level and dura- Th2-dependent responses (e.g., parasite- and antigen-
specific responses as well as IgE production) in CD1-tion of cytokine production, ability to be regulated by
interacting T cells and APCs, or other factors (e.g., bac- deficient mice (Brown et al., 1996; Bendelac et al., 1997;
Smiley et al., 1997), T cell IL-4 secretion is markedlyterial infection) in the various Th1 and Th2 cell popula-
diminished in CD1-deficient mice (Chen et al., 1997;tions examined.
Mendiratta et al., 1997; Smiley et al., 1997). NK-T cells
are diminished in number and decreased in frequency
How Can Regulatory CD41 Th2 Cells Become prior to the onset of disease in several murine models
Progressively Unresponsive and Ineffective of autoimmunity (Takeda and Dennert, 1993; Gombert
in the Face of Autoreactive Thl Cells? et al., 1996b; Mieza et al., 1996; Vicari and Zlotnik, 1996;
If autoimmunity develops from a simple failure of nega- Bendelac et al., 1997). In these models, autoimmunity
tive selection in the thymus, it is difficult to explain why is temporally accelerated by depletion of NK-T cells.
there is little evidence of autoimmune reactivity in the IDDM in NOD mice may also be prevented by adoptive
pancreas of the NOD mouse throughout the first 3±4 transfer of a cell population containing NK-T cells (Bax-
weeks of life (AndreÂ et al., 1996). This outcome may ter et al., 1997). These sets of data are consistent with
arise from a deficit in regulatory CD41 Th2 cell function. the notions that differentiation of T cells into IL-4±
This deficit might be regulated by early events in T cell secreting Th2 cells requires IL-4 priming and that IL-4
differentiation, which may elicit a dominance in the num- produced by NK-T cells stimulates Th2 cell differentia-
tion and protects from autoimmune disease.ber and function of diabetogenic Th1 cells relative to
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An alternative explanation has been proposed for the al., 1993). Such an imbalance may elicit a loss of immu-
noregulation of pathogenic islet-reactive T cells and trig-mechanism of action of NK-T cells. Rather than contrib-
ger the development of destructive insulitis and IDDMuting solely to the generation of Th2 cells, NK-T cells
according to a model shown in Figure 1. Thus, youngmay expand or maintain the survival or function of regu-
nondiabetic NOD mice possess normal levels of func-latory Th2 cells and down-regulate islet-infiltrating ef-
tional regulatory CD41 T cells until about 4±6 weeks offector Th1 cells (Bach et al., 1997). A relative absence
age, and then this T cell function declines rapidly as theof NK-T cells during the first few weeks of life of an NOD
first islet antigen±autoreactive T cells are detected.mouse may upset this Th1/Th2 balance, initiate events
An important cytokine that may be involved in thethat lead to immune dysregulation, and thereby influ-
regulation of some of the age-related functional defi-ence the onset of IDDM.
ciencies of NOD T cells is TNFa. TNFa increases T cellImmune dysregulation and the onset of IDDM may
autoreactivity to islet cells and exacerbates IDDM whenresult from several functional deficiencies in NOD mice
administered in low doses from birth to 3 weeks during(Table 1), which may generate an imbalance between
neonatal life in NOD mice, while administration of anti-autoimmune islet b cell±reactive T cells and the factors
TNFa during this same neonatal period completely pre-(cells and cytokines) that normally keep these T cells in
vents the development of IDDM (Yang et al., 1994). Incheck (AndreÂ et al., 1996; Arreaza et al., 1996; Bergerot
contrast, the administration of TNFa to adult NOD miceet al., 1997). At the onset of insulitis, the number of CD41
($6 weeks of age) blocks the development of IDDM,T cells in NOD peripheral lymphoid organs increases
whereas anti-TNFa exacerbates IDDM in adult NOD(Zhang et al., 1994), and this increase subsides after the
mice.onset of IDDM (Zipris et al., 1991a). Coincident with the
How may these paradoxical age-related differences inappearance of insulitis at about 4±6 weeks of age, a
susceptibility and resistance to IDDM by TNFa treatmentdefective syngeneic mixed lymphocyte reaction (SMLR)
be explained? It is known that chronic TNFa exposureresponse is detectable in NOD mice (Bergerot et al.,
can down-regulate T cell effector function (decreased1997). This age-related defect resides in an SMLR re-
proliferation and reduced Th1 and Th2 cytokine produc-sponder spleen and mesenteric lymph node±derived
tion), while chronic anti-TNFa exposure, by blockingCD41 T cell population (Bergerot et al., 1997), is charac-
engenous TNFa, can up-regulate antigen-specific T cellterized by reduced IL-2 production by these T cells (Ser-
responses and thereforeup-regulate T cell effector func-reze and Leiter, 1988), and correlates closely with in-
tion (Cope et al., 1997a). Based on these findings, it hascreased progression to IDDM (Baxter et al., 1989). These
been proposed that TNFa in neonatal mice may act asobservations may explain why splenic CD41 T cells from
a growth factor for T cells in the thymus, specific foronly young (younger than 4±5 weeks old) NOD female
both self and foreign antigens; augment peripheral Tmice are able to suppress or delay the transfer of IDDM
cell effector function by increasing the expression of(Boitard et al., 1989). In an SMLR response, T cellsprolif-
integrins and selectins; and enhance the homing of acti-erate in response to self±MHC class II, inducing the
vated T cells to the pancreas (Cope et al., 1997b). Anti-activation of regulatory T cells. As a result of the weak
TNFa blocks these effects and prevents primary folliclepeptide-binding properties of I-Ag7 molecules, the affin-
and germinal center formation in lymph nodes. This anti-ity of T cells for I-Ag7 molecules on interacting APCs in
TNFa treatment presumably decreases autoreactive BNOD mice may be too low to trigger the secretion of
cell formation and associated B cell APC function andnormal levels of several cytokines, including IL-2 and
may also interfere with the development and migrationIL-4, and to generate functionally competent regulatory
of autoreactive T cells to the pancreas.CD41 T cells. Thus, a deficiency in, rather than an ab-
Since chronic exposure to TNFa and anti-TNFa re-
sence of, regulatory CD41 T cells is manifested during
duces and augments signaling through the TCR, respec-
an SMLR response in NOD mice greater than 6 weeks
tively (Cope et al., 1997a), an alternate scheme to ex-
of age (Bergerot et al., 1997). A similar peripheral immu-
plain the effects of TNFa and anti-TNFa in neonatal and
noregulatory defect occurs in patients with IDDM (Bow- adult NOD mice has been hypothesized. According to
man et al., 1994). the latter hypothesis, TNFa, which is constitutively ex-
The observation that NOD mice possess defective pressed in the neonatal thymus, may decrease TCR
SMLR responses indicates that they possess a more signaling and negative selection and increase the num-
global defect in CD41 T cell±mediated suppression, and ber of autoreactive T cells that migrate to the periphery
not only a loss of T cell specific tolerance to islet b and possibly also thepancreas ina neonatal NOD mouse
cell autoantigens (Bergerot et al., 1997). Interestingly, (Cope et al., 1997b). These effects may be blocked neo-
all NOD mice, irrespective of age, sex, and disease pro- natally by anti-TNFa and lead to increased negative se-
gression, possess islet cell±reactive CD41 T cells in pe- lection and protection from IDDM. In an adult NOD
ripheral lymph nodes, and similar reactivity occurs in mouse, TNFa-mediated reduction in TCR signaling may
non±diabetes-prone mouse strains (Burtles et al., 1992). decrease autoreactive T cell effector function and inhibit
In these strains as well as in NOD mice greater than 6 the onset of IDDM, whereas anti-TNFa may exacerbate
weeks of age, cells from nonislet tissues fail to activate IDDM by increasing TCR signaling and stimulate autore-
syngeneic T cells in an SMLR. The onset of deficient active T cell effector function. Thus, in an age-depen-
regulatory CD41 T cell function at an early age may dent manner, endogenous TNFa might be able to alter
disrupt the T cell balance required to maintain self-toler- the thresholds required for negative and positive T cell
ance and thereby augment early T cell autoreactivity to selection in the thymus and in this way shape the autore-
active T cell repertoire and susceptibility or resistanceislet cell autoantigens (Kaufman et al., 1993; Tisch et
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Figure 1. Model of Immune Dysregulation of
T Cells Leading to Islet b Cell Destruction and
Onset of IDDM in NOD Mice
Immunologic self-tolerance to pancreatic b
cells is normally maintained by CD41 regula-
tory Th2 T cells, which suppress the activa-
tion of CD41 autoreactive Th1 T cells. In the
NOD mouse, a Th1/Th2 imbalance occurs in
the thymus and periphery and leads to a pro-
gressive, age-dependent elimination of func-
tion of regulatory Th2 T cells. Autoreactive
Th1 T cells become activated and mediate
pancreatic islet b cell destruction by partici-
pating in the recruitment of activated macro-
phages (Mw) and cytotoxic T lymphocytes
(CTLs), and these Th1 cells also help B cells
to produce IgG2a autoantibodies (Y) against
islet b cell autoantigens. Finally, the loss of
Th2 T cell±mediated immunoregulation leads
to a spreading of autoreactivity to islet b cell
autoantigens that ultimately results in the on-
set of IDDM. (1), positive regulation; (2), neg-
ative regulation.
to IDDM. Studies of the effects of TNFa on negative transgenes alone (Guerder et al., 1994), in agreement
with the result that the TNFa gene is tightly linked to anand positive selection and of the possible role of this
cytokine in controlling the function of regulatory CD41 IDDM susceptibility locus (Nistic et al., 1996). It stands to
reason, therefore, that if the binding of islet autoantigenTh2 cells as well as certain othercytokines, chemokines,
and their specific receptors in the periphery are prob- peptides to I-Ag7 preferentially up-regulates B7±1 ex-
pression, this may limit B7±2 expression and Th2 celllems that merit further investigation.
development as well as activate other factors that po-
tentiate the onset of IDDM. This idea is supported byDoes the Lack of Costimulation by CD28 or
CTLA-4 Mediate the Onset of IDDM? the observations that IDDM is exacerbated in CD28-
deficient NOD mice (Lenschow et al., 1996) and thatDifferential CD28-B7 costimulation for Th1 or Th2 devel-
opment may be controlled by at least two candidate IDDM is prevented by the administration of an activating
anti-CD28 monoclonal antibody to young (2±4 week-non-MHC IDDM susceptibility loci. CTLA-4 is a negative
regulator of T cell activation and autoreactivity, and a old) but not older ($5 week-old) NOD mice (Arreaza et
al., 1997). Thus, the coupled effects of peptide bindingmutation in the CTLA-4 gene may be associated with sus-
ceptibility to IDDM in humans (Nistic et al., 1996; Todd to I-Ag7, deficiency in CD28 signaling and impairment in
negative regulation by CTLA-4 of T cell activation mayand Farrall, 1996; Donner et al., 1997). The Idd-5 non±
MHC-linked diabetogenic locus, which colocalizes with result in the insufficient costimulation, higher threshold
of activation, resistance to apoptosis, and associatedthe CD28 and CTLA-4 genes on mouse chromosome 1,
controls resistance to cyclophosphamide-induced apo- defect in proliferation and function of regulatory Th2
cells found in NOD mice.ptosis of NOD lymphocytes (Colucci et al., 1997). The
expression of CTLA-4 and CD28 is defective in NOD Predictably, the net outcome of these coupled effects
is similar to that which occurs in CTLA-4 deficient mice:mice, suggesting that one or both of these molecules
may be involved in the control of apoptosis resistance, namely, the dysregulation of costimulation, leading to
the strong activation of T cells that mediate tissue de-thymocyte selection, and IDDM susceptibility. Consis-
tent with these notions, administration of soluble CTLA- struction and autoimmune disease. In NOD mice, the
outcome is the progression from a nondestructive peri-4-Ig to young NOD mice prevents IDDM (Lenschow et al.,
1995), and IDDM is enhanced in CTLA-4-Ig transgenic insulitis, which persists until about 10±13 weeks of age,
to a very invasive insulitis and then destructive insulitisNOD mice (Lenschow et al., 1996).
Coexpression of B7-1 with TNFa in the pancreas in- that within the next 3 weeks initiates the onset of IDDM
in about 80% of females (Bach et al., 1997; Gazda etcreases the incidence of IDDM in transgenic NOD mice
compared with the expression of either one of these al., 1997; Lafferty, 1997). The possibility that an increase
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in CTLA-4 expression by Th2 cells mediates the appear- cells from NOD mice and humans with IDDM. This in-
crease in the number of peripheral T cells may ariseance of invasive and destructive insulitis deserves fur-
ther consideration. from the weak peptide-binding affinity of I-Ag7 molecules
on NOD APCs and the resulting reduced capacity of
APCs in the thymus of NOD mice to negatively select TDoes an IDDM-Susceptibility Locus Control the
cells with potential reactivity to islet autoantigens. WhileProgression from Nondestructive Insulitis
unresponsiveness to peptide/I-Ag7 complexes may pre-to Destructive Insulitis and the Onset of IDDM?
clude stimulation of autoreactive T cells to a sufficientlyDeficient regulatory T cell±dependent control of autore-
high threshold level to induce their deletion, the levelsactive effector T cells can elicit various autoimmune
of activation reached by these T cells may suffice todiseases depending on the genetic makeup of the host
render them anergic to subsequent TCR stimulation.(Sakaguchi et al., 1996). Accordingly, the failure in T cell
Nonetheless, this anergic state resulting from a failureregulation and escape from islet b cell tolerance in NOD
of central and peripheral tolerance mechanisms remainsmice is also regulated by several (at least 16) IDDM-
capable of maintaining the autoimmune phenotype ofsusceptibility and IDDM-resistant loci (Todd et al., 1991;
these T cells. These T cells may still retain the capacitySerreze and Leiter, 1994; Ikegami et al., 1995; Wicker
to initiate and contribute to the development of autoim-et al., 1995; Denny et al., 1997). Is it possible to identify
mune disease.which of these loci are involved in the regulation of
Numerous fundamental questions related to IDDM re-progression from nondestructive insulitis to destructive
main to be explored in the NOD mouse model, andinsulitis and the onset of IDDM?
include the following. (1)Are I-Ag7 MHC class II moleculesA partial answer to this question has been provided
underexpressed on the cell surface of APCs, and if so,by studies of the geneticcontrol of theabove-mentioned
is this the result of their generally low peptide-bindingTCR-dependent NOD T cell proliferative hyporespon-
affinity and inherent instability? Does this weak bindingsiveness. This hyporesponsiveness trait of NOD T cells
affinity for peptides mediate the positive selection andwas found to colocalize with the Idd-4 non-MHC diabe-
exit into the periphery of an increased number of islettogenic locus, which maps to the central region of
autoantigen reactive T cells? (2) What are the criticalmouse chromosome 11 and includes the CC b-chemo-
autoantigens in IDDM, and is there a primary autoanti-kine gene family (Gill et al., 1995). This proliferative de-
gen that induces the onset of IDDM? (3) What are thefect is intrinsic to T cells and results from the reduced
mechanisms of induction of islet b cell death, and whichability of NOD T cells to activate TCR-coupled protein
pathways (e.g., Fas/FasL, TNF/TNF receptor, or perforin)kinase C± and Ras-mediated second messenger signal-
are most relevant to b cell apoptosis? (4) What agents,ing pathways (Rapoport et al., 1993b; Salojin et al.,
internal or external (e.g., viral, bacterial, or diet), trigger1997b). This may explain why IL-2 secretion is greatly
the onset of inflammation and IDDM? (5) What is thereduced in TCR-stimulated NOD T cells, in keeping with
antigenic specificity and mechanism of action of regula-the possibility that IL-2 may be the candidate non-MHC
tory T cells that may mediate protection from IDDM? (6)diabetogenic gene in the Idd-3 locus on mouse chromo-
Finally, which cytokines and chemokines are most activesome 3 (Denny et al., 1997). Preliminary analyses sug-
in the down-regulation of the autoimmune response,gest that a relatively high level of intrapancreatic ex-
and what is their mechanism of action? These and otherpression of the MIP-1b chemokine and low level of the
questions will direct our exploration of the mechanismsMIP-1a chemokine is associated with nondestructive
underlying IDDM and other autoimmune diseases.peri-insulitis, whereas high intrapancreatic concentra-
tions of MIP-1b and low concentrations of MIP-1b are
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